T1	p 74 140	patients with chemotherapy-induced painful peripheral neuropathy :
T2	p 468 686	8 National Cancer Institute ( NCI ) -funded cooperative research networks that enrolled 231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011 . Study
T3	p 711 722	July 2012 .
T4	p 763 781	comorbid pain risk
T5	p 920 928	patients
T6	p 934 1042	grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and
T7	p 1065 1069	of 0
T8	p 1078 1187	representing average chemotherapy-induced pain , after paclitaxel , other taxane , or oxaliplatin treatment .
T9	p 2283 2325	patients with painful chemotherapy-induced
T10	i 16 26	duloxetine
T11	i 316 326	duloxetine
T12	i 430 448	placebo-controlled
T13	i 827 868	duloxetine followed by placebo or placebo
T14	i 881 891	duloxetine
T15	i 1133 1145	paclitaxel ,
T16	i 1152 1187	taxane , or oxaliplatin treatment .
T17	i 1244 1259	1 capsule daily
T18	i 1270 1300	30 mg of duloxetine or placebo
T19	i 1354 1381	duloxetine or placebo daily
T20	i 1501 1508	placebo
T21	i 1942 1949	placebo
T22	i 2065 2072	placebo
T23	i 2204 2211	placebo
T24	i 2386 2393	placebo
T25	o 30 67	pain , function , and quality of life
T26	o 234 276	chemotherapy-induced peripheral neuropathy
T27	o 354 369	pain severity .
T28	o 1099 1124	chemotherapy-induced pain
T29	o 1523 1587	chemotherapy-induced peripheral neuropathic pain . Pain severity
T30	o 1617 1660	Pain Inventory-Short Form average pain item
T31	o 1684 1688	pain
T32	o 1840 1852	average pain
T33	o 2023 2041	average pain score
T34	o 2231 2251	pain of any amount .
T35	o 2305 2347	chemotherapy-induced peripheral neuropathy
T36	o 2441 2445	pain